The Journal of Health Technology Assessment (보건의료기술평가)

Korean Association of Health Technology Assessment (한국보건의료기술평가학회)
권호 표지

The Effects of Nafamostat Mesilate on a Bleeding Risk as an Anticoagulant During Use as a Continuous Renal Replacement Therapy: Systematic Review

  • Kang, YoungJu (Social Pharmacy, College of Pharmacy, Yonsei University) ;
  • Moon, Su Jee (Social Pharmacy, College of Pharmacy, Yonsei University) ;
  • Kang, Hye-Young (Social Pharmacy, College of Pharmacy, Yonsei University)
  • Received : 2018.03.29
  • Accepted : 2018.08.20
  • Published : 2018.12.31

⟨ Previous Next ⟩

Abstract

Objectives: In the past, the pharmaceutical drug heparin was mostly used as the anticoagulant for continuous renal replacement therapy (CRRT), but the duration time is long to have the risk of a bleeding adverse effect, and in that case the drug therapy Nafamostat mesilate was utilized instead, as it is more safe in this case, with a short half-life and is increasing in use to permit lower concerns for bleeding incidents. However, there are insufficient number of large-scale studies on the comparison of Nafamostat mesilate and heparin. Methods: In this study, a systematic review are used to compare the bleeding risk of Nafamostat mesilate and Heparin, as subjected to patients and procedures for measuring risks performed with a CRRT, and the filter life span is to be evaluated as well in this patients. Results: As a result of literature review search, a total of 6 studies were included in systematic review. The reducing risk of bleeding and filter life span was analyzed. The retrospective cohort studies confirm that Nafamostat mesilate is less at risk of bleeding than heparin. And a cohort study confirms that Nafamostat mesilate is longer filter lifespan than heparin and randomized controlled trial studies show that Nafamostat mesilate is longer filter lifespan than not using the anticoagulants. Conclusion: Nafamostat mesilate is considered to be a good therapeutic option because it has a longer filter life span as well as the advantage of reducing bleeding.

Keywords

References

  1. Schetz M, Lauwers PM, Ferdinande P. Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view. Intensive Care Med 1989;15:349-357.
  2. Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009;22:141-145. https://doi.org/10.1111/j.1525-139X.2008.00545.x
  3. Van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7:145-150.
  4. Reeves JH, Cumming AR, Gallagher L, O’Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999;27:2224-2228. https://doi.org/10.1097/00003246-199910000-00026
  5. Journois D, Safran D, Castelain MH, Chanu D, Drevillon C, Barrier G. Comparison of the antithrombotic effects of heparin, enoxaparin and prostacycline in continuous hemofiltration. Ann Fr Anesth Reanim 1990;9:331-337. https://doi.org/10.1016/S0750-7658(05)80244-8
  6. Van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH, Kingma WP, Boerma EC. Filter run time in CVVH: pre-versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif 2005;23:175-180.
  7. Kim HC, Han SY, Kim HK, Cho WY, Sung SA, Park SK, et al. A multi-center phase III clinical trial to assess the influence to bleeding and anticoagulant effect of Nafamostat Mesilate (Futhan) in hemodialysis patients with high bleeding-risk. Korean Renal Med 2004;6:920-926.
  8. Okada H, Suzuki H, Deguchi N, Saruta T. Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate. Nephrol Dial Transplant 1992;7:980.
  9. Park II, Choi MJ, Yoon JW, Lee YK, Kim SG, Oh JE, et al. Saline versus nafamostat mesilate anticoagulation for continuous veno-venous hemofiltration (CVVH) in patients at high risk of bleeding: a prospective study. Korean J Nephrol 2009;28:205-210.
  10. Kinnunen EM, Juvonen T, Airaksinen KE, Heikkinen J, Kettunen U, Mariscalco G, et al. Clinical significance and determinants of the universal definition of perioperative bleeding classification in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2014;148:1640-1646. https://doi.org/10.1016/j.jtcvs.2014.07.040
  11. Fealy N, Aitken L, Toit Ed, Baldwin I. Continuous renal replacement therapy: current practice in Australian and New Zealand intensive care units. Crit Care Resusc 2015;17:83-91.
  12. Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail 2012;34:279-285. https://doi.org/10.3109/0886022X.2011.647293
  13. Lee SH, Kwon SK, Kim HY. Outcome and prognosis in patients receiving continuous renal replacement therapy. Kidney Res Clin Pract 2010;29:434-440.
  14. Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs 2016;39:16-21. https://doi.org/10.5301/ijao.5000465
  15. Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs 2013;36:208-216. https://doi.org/10.5301/ijao.5000191
  16. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007;33:1563-1570. https://doi.org/10.1007/s00134-007-0754-4
  17. Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991;93:215-217.
  18. Lee YK, Lee HW, Choi KH, Kim BS. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One 2014;9:e108737. https://doi.org/10.1371/journal.pone.0108737
  19. Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine (Baltimore) 2015;94:e2392 https://doi.org/10.1097/MD.0000000000002392